Biocompatibility evaluation of medical plastics is a mandatory step in demonstrating that polymer-based medical devices and their extractable constituents do not induce cytotoxic, sensitizing, irritant, hemolytic, or systemic adverse effects in patients. Guided primarily by the ISO 10993 series of standards, the evaluation integrates chemical characterization, in vitro assays, and in vivo testing to support regulatory submissions worldwide. This article provides a comprehensive technical review of the standards framework, sample requirements, core test items, analytical methods, and typical applications of biocompatibility assessment for medical-grade plastics.
Technical Overview
Biocompatibility is defined as the ability of a material to perform its intended function within a medical application with an appropriate host response, without producing unacceptable local or systemic effects. For medical plastics, biocompatibility is not an intrinsic property of the polymer itself; it depends on the complete material formulation, including residual monomers, oligomers, plasticizers, antioxidants, stabilizers, colorants, processing aids, adhesive residues, and degradation products that may migrate out of the plastic during clinical use. Because these leachable substances can elicit cytotoxicity, irritation, sensitization, hemolysis, or genotoxic responses, a structured biological safety evaluation is required before a plastic medical device can be placed on the market.
The internationally recognized framework for this evaluation is the ISO 10993 series of standards, which has been adopted in China as the GB/T 16886 series and is referenced by major regulatory authorities including the U.S. Food and Drug Administration (FDA) and the European Union Medical Device Regulation (MDR). ISO 10993-1 establishes the risk-based evaluation process: the device is first categorized according to the nature of body contact (surface devices, externally communicating devices, or implant devices) and contact duration (limited, meaning up to 24 hours; prolonged, meaning 24 hours to 30 days; or permanent, meaning more than 30 days). Based on this categorization, a panel of biological endpoints is selected from the ISO 10993-1 test selection matrix.
Modern practice, reinforced by the 2020 revision of ISO 10993-1 and the corresponding FDA guidance, emphasizes a chemical characterization-first approach. Quantitative analysis of extractables and leachables under ISO 10993-18, followed by toxicological risk assessment under ISO 10993-17, allows many biological endpoints to be justified by chemistry data, reducing unnecessary animal testing while strengthening the scientific basis of the safety claim. All results must be interpreted within the manufacturer's overall risk management system, consistent with ISO 14971.
Testing Samples
Raw Materials and Resins
Biocompatibility evaluation typically begins at the material level. Medical-grade resins such as polyvinyl chloride (PVC), polypropylene (PP), polyethylene (PE), polycarbonate (PC), thermoplastic polyurethane (TPU), silicone elastomers, polyetheretherketone (PEEK), polystyrene, and cyclic olefin copolymers are characterized for their base polymer identity, additive package, and residual monomer content. Material master files and supplier declarations provide the starting point, but analytical verification is usually performed by accredited third-party laboratories to confirm composition claims.
Finished Device Components
Whenever possible, testing is conducted on the finished device in its final processed, assembled, colored, and sterilized condition, because molding, extrusion, printing, solvent bonding, and sterilization can all alter the toxicological profile of the plastic. Representative finished components include syringe barrels and plungers, intravenous (IV) tubing and drip chambers, catheter shafts, luers and needle hubs, dialyzer housings, implant bodies, and sterile barrier packaging.
Extracts and Leachables
Most biological tests are performed not on the plastic directly but on liquid extracts prepared under standardized conditions defined in ISO 10993-12. Polar extraction vehicles (such as sodium chloride injection or culture medium) and non-polar vehicles (such as sesame or cottonseed oil) are used in parallel to simulate both aqueous tissue contact and lipid contact. Additional vehicles such as ethanol/water or ethanol/saline mixtures may be used for exhaustive extraction in chemical characterization studies.
Materials Requiring Special Attention
Certain plastic-related situations demand expanded evaluation:
- Plasticized PVC, due to migration of phthalate plasticizers such as DEHP and alternative esters like TOTM, particularly in blood-contacting and neonatal applications.
- Polycarbonate and epoxy-cured systems, due to residual bisphenol A concerns.
- Radiation-sterilized polymers, which may generate oxidative degradation products after gamma or electron-beam exposure.
- Colored and radiopaque compounds containing titanium dioxide, barium sulfate, or bismuth-based fillers.
- Devices sterilized with ethylene oxide, which require residual EtO and ethylene chlorohydrin analysis under ISO 10993-7.
- Biodegradable and absorbable polymers, which require degradation product characterization under ISO 10993-9 and ISO 10993-13.
Testing Items
The endpoint panel for a medical plastic device is driven by the ISO 10993-1 categorization matrix. The principal test items and their governing standards are listed below:
- Cytotoxicity (ISO 10993-5): assessment of cell viability and morphology after exposure to material extracts or direct material contact; a reduction in cell viability greater than 30 percent classifies the sample as potentially cytotoxic.
- Sensitization (ISO 10993-10): evaluation of delayed-type hypersensitivity potential, typically via the guinea pig maximization test, the Buehler closed-patch test, or the murine local lymph node assay (LLNA).
- Irritation and intracutaneous reactivity (ISO 10993-23): determination of local inflammatory response using intracutaneous injection in rabbits or validated in vitro reconstructed human epidermis models for skin irritation.
- Acute, subacute, and subchronic systemic toxicity (ISO 10993-11): single-dose or repeated-dose (14 to 90 day) studies assessing systemic effects of extractable substances.
- Genotoxicity (ISO 10993-3): a battery combining the bacterial reverse mutation (Ames) assay with mammalian assays such as in vitro chromosomal aberration, mouse lymphoma, or micronucleus tests, escalated to in vivo testing when warranted.
- Hemocompatibility (ISO 10993-4): hemolysis testing, complement activation, coagulation, platelet interaction, and thrombogenicity assessment for blood-contacting plastics.
- Material-mediated pyrogenicity (ISO 10993-11): rabbit pyrogen testing to detect non-endotoxin heat-transmitting substances, supplemented by compendial bacterial endotoxin (LAL) testing where applicable.
- Implantation testing (ISO 10993-6): local tissue response evaluation at implant sites over short-term (1 to 4 weeks), subchronic (12 to 26 weeks), or long-term durations, relevant for implantable plastics such as PEEK and UHMWPE.
- Chronic toxicity and carcinogenicity (ISO 10993-11, ISO 10993-3): long-duration studies required only for permanent-contact devices where risk assessment indicates a need.
- Chemical characterization and extractables/leachables studies (ISO 10993-18, ISO 10993-17): identification and quantification of organic and inorganic leachables, followed by dose-based toxicological risk assessment.
- Ethylene oxide residue testing (ISO 10993-7): quantification of EO, ECH, and EG residuals on gas-sterilized plastics against permissible exposure limits.
- Degradation testing (ISO 10993-9, ISO 10993-13): characterization of degradation products and kinetics for absorbable or hydrolytically unstable polymers.
Testing Methods
Sample Preparation and Extraction
Extraction is the critical first step for most assays. ISO 10993-12 prescribes standardized surface-area-to-volume ratios, commonly 3 to 6 cm² of material per milliliter of vehicle depending on wall thickness, or approximately 0.2 g of material per milliliter for irregularly shaped articles. Standard extraction conditions include 37 °C for 72 hours, 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour, selected to exaggerate clinical leaching without inducing thermal degradation of the polymer. Hollow devices such as tubing are extracted by filling the lumen, and final-product extracts are prepared after the device has undergone its validated sterilization process.
Cytotoxicity Testing
The predominant method is the elution assay using mammalian fibroblast cultures such as L929 cells. Extracts are dosed onto monolayers for 24 to 48 hours, and viability is quantified by MTT, neutral red uptake, or similar colorimetric endpoints, supported by morphological scoring. Agar diffusion and direct contact methods, described in ASTM F813 and ASTM F895, remain useful for evaluating contact-mediated toxicity. A quantitative result above 70 percent relative viability indicates the material is not cytotoxic.
Sensitization and Irritation Testing
Sensitization is most commonly assessed by the LLNA, in which proliferation of draining lymph node cells is measured after topical extract exposure; a stimulation index of three or greater indicates sensitization potential. Guinea pig methods remain acceptable alternatives. For irritation, ISO 10993-23 now permits in vitro reconstructed human epidermis models as a replacement for the rabbit skin test for many device categories, while intracutaneous reactivity testing in rabbits continues to be applied to extracts from devices contacting breached tissue or blood pathways.
Hemocompatibility Testing
Hemolysis is evaluated by the direct contact and extract methods, measuring hemoglobin release from rabbit or human erythrocytes after incubation at 37 °C, in accordance with ISO 10993-4 and ASTM F756; a hemolysis index below five percent is generally regarded as non-hemolytic. Blood-contacting plastics such as extracorporeal circuit tubing, oxygenator housings, and IV catheters may additionally require complement activation (C3a, SC5b-9), partial thromboplastin time, platelet adhesion, and thrombogenicity assessment under dynamic flow conditions.
Chemical Characterization and Toxicological Assessment
Extractables studies apply exhaustive or simulated-use extraction followed by chromatographic and spectrometric analysis: gas chromatography–mass spectrometry (GC-MS) for volatile and semi-volatile organics, liquid chromatography–mass spectrometry (LC-MS/MS) for non-volatile and thermally labile compounds, and inductively coupled plasma mass spectrometry (ICP-MS) for elemental impurities and catalyst residues. Extractable profiles are then compared with the toxicological evaluation thresholds under ISO 10993-17 to derive safety margins for each detected compound. This analytical dossier frequently allows waiver of in vivo systemic toxicity studies and accelerates evaluation of supplier or formulation changes. ASTM F748 provides complementary guidance on selecting generic biological test methods for polymeric materials.
Applications
Biocompatibility evaluation of medical plastics supports safety demonstration across the full spectrum of polymer-based healthcare products:
- Infusion, transfusion, and injection devices: IV administration sets, blood bags and tubing, syringes, infusion pump cassettes, and prefilled syringe components, where PVC, PP, and TPU dominate.
- Vascular and intravascular catheters: central venous, peripheral, and hemodialysis catheters requiring rigorous hemocompatibility and systemic toxicity data.
- Extracorporeal circuits: dialysis blood lines, oxygenator housings, and apheresis consumables with prolonged circulating-blood contact.
- Implantable devices: PEEK spinal cages and cranial plates, UHMWPE orthopedic bearing surfaces, silicone aesthetic implants, and absorbable fixation devices, requiring implantation and degradation testing.
- Drug delivery systems: metered-dose inhaler components, insulin pen bodies, transdermal backing films, and parenteral nutrition containers, where leachables may interact with the drug product.
- Respiratory and anesthesia equipment: masks, breathing circuits, humidifier chambers, and ventilator components contacting mucosal surfaces.
- Wound care and topical products: films, hydrocolloid backings, and adhesive matrices contacting breached skin.
- In vitro diagnostic consumables: cuvettes, microfluidic chips, reagent reservoirs, and sample collection tubes, often qualified under a reduced endpoint panel justified by contact analysis.
- Sterile barrier packaging: thermoform trays, lids, and films whose extractables may transfer to the enclosed device.
FAQ
Q: Which standard governs the biocompatibility evaluation of medical plastics?
A: The ISO 10993 series is the primary international framework, with ISO 10993-1 defining the evaluation plan and endpoint selection. In China, the equivalent GB/T 16886 series applies and is technically aligned with ISO 10993. Older procurement specifications sometimes reference USP Class VI biological reactivity testing, but regulators now expect the broader, risk-based ISO 10993 approach.
Q: How is the appropriate test panel selected for a plastic device?
A: The device is classified by body-contact type (surface, external communicating, or implant) and contact duration (limited, prolonged, or permanent) per ISO 10993-1. The resulting matrix, combined with chemical characterization and toxicological risk assessment, determines which endpoints require testing and which can be justified analytically.
Q: How long does biocompatibility testing take?
A: Cytotoxicity typically requires two to four weeks, irritation four to six weeks, and sensitization six to ten weeks. Genotoxicity batteries, subchronic studies, and implantation studies can extend the timeline from three months to more than one year, which is why early chemical characterization and evaluation planning are strongly advised.
Q: If the plastic supplier or resin grade changes, must testing be repeated?
A: A change in resin grade, formulation, processing, or sterilization invalidates prior conclusions unless equivalence can be demonstrated. Comparative chemical characterization under ISO 10993-18, reviewed against ISO 10993-17, may confirm equivalence without full retesting; otherwise, targeted biological tests are repeated.
Q: Can chemical characterization replace animal testing?
A: In many cases, yes. Current ISO 10993-1 guidance and FDA policy accept chemistry-plus-toxicology justification for endpoints such as acute and subacute systemic toxicity. However, sensitization, certain irritation scenarios, and implantation responses generally still require in vivo or validated in vitro biological data.
Q: Which extraction conditions are used, and why both polar and non-polar vehicles?
A: ISO 10993-12 defines standard conditions such as 37 °C for 72 hours or 50 °C for 72 hours to simulate or exaggerate clinical exposure. Polar vehicles model aqueous tissue environments, while non-polar vehicles model lipid-rich contact, ensuring that both hydrophilic and lipophilic leachables are captured in the biological evaluation.